The present invention relates to compositions and methods for treating microbial infections in subjects, in particular methods of administering a gelsolin agent and an antimicrobial agent to produce a synergistic therapeutic effect against a microbial infection in a subject. The present invention also relates to methods for treating viral infections in subjects, including methods that include delayed-dosing methods and/or synergistic methods.

Disclosed herein is a compound of formula I:

##STR00001##

where m, n and R.sup.1 are as defined herein. Also disclosed herein are uses of the compound.

Disclosed herein is a compound of formula I:

##STR00001##

where m, n and R.sup.1 are as defined herein. Also disclosed herein are uses of the compound.

Pharmaceutical compositions comprising amphiphilic peptides are provided. The pharmaceutical compositions are useful in treating or preventing various orthopedic and dental-related infectious and/or inflammatory conditions.

Pharmaceutical compositions comprising amphiphilic peptides are provided. The pharmaceutical compositions are useful in treating or preventing various orthopedic and dental-related infectious and/or inflammatory conditions.

The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III/IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions.

The present invention relates to a technology for oral delivery of Poorly Bio-Available Therapeutic Agents and the formulations derived using this technology. Poorly Bio-Available Therapeutic Agents may belong to BCS class III/IV drugs or nutraceutical or any other agent which is required to be orally delivered having challenge of bio-availability in body. Therefore, invention further relates to a targeted delivery technology for enhanced bio-availability and controlled release without being degraded. The present invention further relates to the processes for the preparation of said compositions and formulations made thereof. The formulations of the present invention are useful to treat related conditions.

Provided herein are compounds, compositions, and methods useful for reducing, preventing, and/or inhibiting germination of C. difficile spores, including methods for inhibiting C. difficile germination to prevent or treating C. difficile-associated diseases and disorders such as, for example, severe diarrhea and colitis in a subject. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Provided herein are compounds, compositions, and methods useful for reducing, preventing, and/or inhibiting germination of C. difficile spores, including methods for inhibiting C. difficile germination to prevent or treating C. difficile-associated diseases and disorders such as, for example, severe diarrhea and colitis in a subject. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.